30 June 2025

PharmaSGP Holding SE holds 2025 Annual General Meeting

Corporate News

- 91.12% of the registered share capital was represented

- Minimum dividend of €0.05 per dividend-bearing share resolved

- Management Board reports on successful operational development in 2024; forecast for current fiscal year 2025 confirmed


Gräfelfing, June 26, 2025 – German OTC pharmaceutical company PharmaSGP Holding SE held its 2025 Annual General Meeting yesterday as an in-person event at its headquarters in Gräfelfing. The share capital represented amounted to 91.12%.

At the Annual General Meeting, the Management Board reported on the successful 2024 financial year. Compared to the previous year, revenues grew by 17.5% to €118.8 million (previous year: €101.1 million). Adjusted earnings before interest, taxes, depreciation, and amortization (adjusted EBITDA) also increased by 9.2% from €34.1 million in 2023 to €37.2 million in fiscal year 2024. The adjusted EBITDA margin was 31.3% (previous year: 33.7%).

In accordance with the existing dividend policy, the Management Board and Supervisory Board had originally proposed to the Annual General Meeting the payment of a dividend of €0.51 per dividend-bearing share. In light of the delisting offer announced on June 10, 2025, FUTRUE GmbH, as the bidder and majority shareholder, submitted a counterproposal at the Annual General Meeting to approve the statutory minimum dividend of €0.05 per PharmaSGP share. This is intended to ensure that PharmaSGP shareholders can be granted the announced offer price of €28.00 per share without deduction of previously distributed dividends. The Annual General Meeting approved the counterproposal and resolved to distribute the statutory minimum dividend of €0.05 per PharmaSGP share.

The company also provided information on its current business development and confirmed its forecast for the ongoing 2025 financial year. The forecast takes into account, among other things, the continuing geopolitical and economic uncertainties. The Management Board expects revenues in a range between €122.0 million and €128.0 million. This represents average growth of around 5% compared with the previous year. Adjusted EBITDA is forecast to be between €37.0 million and €39.0 million. This corresponds to an adjusted EBITDA margin of 28.9% to 32.0%. In the first quarter of 2025, PharmaSGP achieved revenues growth of 10.8% to €33.5 million. Adjusted EBITDA increased by 4.0% to €9.2 million compared to the same period last year. The resulting adjusted EBITDA margin was 27.5% (previous year's quarter: 29.4%).

The detailed voting results for the Annual General Meeting 2025 are available for download on PharmaSGP's corporate website in the Investor Relations / Annual General Meeting section.

28 June 2025

CompuGroup Medical SE & Co. KGaA: CVC successfully concludes public delisting offer for CompuGroup Medical

Corporate News

- CVC has secured total stake of 27.78% of the share capital and voting rights in CompuGroup Medical; founding family Gotthardt retains majority stake of 50.12%

- CVC as second anchor shareholder will support CompuGroup Medical to focus on implementation of its long-term innovation and growth strategy

- Delisting from the regulated market of the Frankfurt Stock Exchange (Prime Standard) effective as of expiry of June 24, 2025

- Following completion of the delisting, CVC will join CompuGroup Medical’s expanded Administrative Board with three seats; founding family Gotthardt will remain in control


Koblenz, Frankfurt – Caesar BidCo GmbH, a holding company owned by investment funds advised and managed by CVC Capital Partners ("CVC"), has announced the final results of the public delisting offer to all shareholders of CompuGroup Medical SE & Co. KGaA ("CompuGroup Medical" or "CGM"). At the end of the acceptance period on June 24, 2025, the delisting offer was accepted for approximately 3.39% of all shares in CompuGroup Medical. In total, CVC has secured a stake of approximately 27.78% of the share capital in CGM via the bidder as of today. The shareholders around the founding family Gotthardt retain their majority stake and continue to hold approximately 50.12% of all shares in CompuGroup Medical. There will be no additional acceptance period, and the delisting offer is not subject to any closing conditions.

The delisting of CompuGroup Medical from the Frankfurt Stock Exchange has become effective as of expiry of June 24, 2025. Following the completion of the delisting from the regulated market of the Frankfurt Stock Exchange (XETRA) and from the segment of the regulated market with additional post-admission obligations (Prime Standard) of the Frankfurt Stock Exchange, the management of CompuGroup Medical has promptly taken action to terminate the inclusion of CGM shares in the open market (Freiverkehr) of the stock exchanges in Berlin (Second Regulated Market), Düsseldorf, Hamburg, Hanover, Munich, Stuttgart, as well as via Tradegate Exchange.

Effective July onwards, the Administrative Board of CompuGroup Medical will expand from five to six members, reflecting the terms of the Investment Agreement with CVC. As part of this agreement, CVC will secure representation on the Administrative Board with three seats. The founding family Gotthardt will retain control of the Administrative Board, represented by three representatives, including Frank Gotthardt as Chairman, Prof. (apl.) Dr. Daniel Gotthardt and Dr. Klaus Esser. Joining the Administrative Board as CVC representatives are Dr. Daniel Pindur, Can Toygar and Christoph Röttele. Together, the Gotthardt family and CVC will bring in their joint expertise to drive the execution of CGM’s long-term growth and innovation strategy.

Frank Gotthardt, Chairman of the Administrative Board of CompuGroup Medical, said: I would like to sincerely thank Stefanie Peters and Prof. (apl.) Dr. med. Karl Heinz Weiss for their support of CGM during their tenure as members of the Administrative Board. I am looking forward to driving innovation and growth together with CVC in the years to come. For no one should suffer or die because at some time medical information was missing.”

Dr. Daniel Pindur, Managing Partner at CVC, said: “With our partnership with CGM and the successful delisting, we are entering the next chapter of CompuGroup Medical’s success story. Together, we will be able to invest in a long-term and strategic manner to expand CGM’s leading market position.” Can Toygar, Partner at CVC, added: “In collaboration with the Gotthardt family, we will focus on investing in the future of the company, driving product development and delivering outstanding solutions for CGM’s customers.”

CGM and CVC first announced their strategic partnership and the planned subsequent delisting of CGM on December 9, 2024. In this context, CVC published a voluntary public tender offer to all CGM shareholders. On April 17, 2025, the bidder announced receiving the final regulatory approval for its voluntary public tender offer. The strategic partnership between CVC and CGM officially came into effect upon completion of the offer on May 2, 2025. Subsequently, CompuGroup Medical and CVC announced the signing of an agreement to delist CGM from the stock exchange on May 8, 2025. For this purpose, CVC launched a public delisting offer to all shareholder of CompuGroup Medical on May 23, 2025.

The completion of the public delisting offer will take place within the next eight banking days, i.e. on July 9, 2025 the latest. Shareholders of CompuGroup Medical who tendered their shares in the public delisting offer will be paid the offer price of EUR 22.00 per share. Further information on the settlement and transfer of the tendered shares is available on the following website: https://www.practice-public-offer.com/en.

About CompuGroup Medical SE & Co. KGaA

CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 1.15 billion in 2024, its software products are designed to support all medical and organizational activities in doctors’ offices, pharmacies, laboratories, hospitals and social welfare institutions. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. The basis of CompuGroup Medical's services is its unique customer base, including doctors, dentists, pharmacists and other healthcare professionals in inpatient and outpatient facilities, as well as insurance and pharmaceutical companies. CompuGroup Medical has offices in 19 countries and offers its solutions in 60 countries worldwide. More than 8,700 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.

About CVC Capital Partners


CVC is a leading global private markets manager with a network of 30 office locations throughout EMEA, the Americas, and Asia, with approximately €200 billion of assets under management. CVC has seven complementary strategies across private equity, secondaries, credit and infrastructure, for which CVC funds have secured commitments of over €260 billion from some of the world's leading pension funds and other institutional investors. Funds managed or advised by CVC’s private equity strategy are invested in approximately 140 companies worldwide, which have combined annual sales of over €168 billion and employ over 600,000 people. CVC has been an established player in the German-speaking region for over 30 years and has successful partnerships with founder- and family-run companies, including Douglas, Europe's leading omnichannel provider of premium beauty, and until recently DKV Mobility, a leading service provider for international mobility, and Messer Industries, a leading global specialist for industrial gases.

12 June 2025

Weng Fine Art: Sale of the Artnet Stake completed

Press Release from June 11, 2025

The sale of the stake in artnet AG (Artnet) has now been completed and the purchase price of almost EUR 20 million for the Artnet shares acquired has been paid to Rüdiger K. Weng and the companies under his control. Weng Fine Art AG (WFA) accounted for EUR 15,187,500 of this amount.

WFA will use the high cash inflow primarily to reduce its bank liabilities and, as a result, will terminate its cooperation with three banks for the time being in the coming months. This will reduce the number of financing partners to three or four banks in the near future. The management plans to invest the remaining part of the income in the development of promising new business areas, among other things. The Management Board will provide details on this later this year.

WFA CEO Rüdiger K. Weng comments on discussions about a potentially even higher takeover price for Artnet shareholders as follows: "In my view, speculation about a possibly higher consideration for the shareholders as part of the takeover process is absurd. Beowolff Capital is likely to have already acquired or been promised more than 70% of the shares by now, so there is no longer any room for any promising counteroffer from any side."

Rüdiger K. Weng's opinion on hopes of a higher price in a possible squeeze-out procedure is as follows: "Hans Neuendorf and Family & Friends have continuously drawn on the assets and income of Artnet for over two decades until both the equity and the cash holdings were completely depleted. Without a capital injection from outside, Artnet would probably have had to file for insolvency within the next few weeks or months. Against this background, the purchase price of EUR 11.25 per share that I negotiated is already optimized and can only be justified by Artnet's very valuable brand and its wealth of data. In contrast, I expect the figures for the operations in 2024 and 2025, which will be published soon, will look catastrophic. Against this background, I consider it extremely unlikely that an even higher price could be achieved in a possible squeeze-out. WFA and I have therefore decided to sell all our shares to Beowolff Capital. However, it is possible that WFA will acquire a stake in the company resulting from the merger of Artnet and Artsy at a later date."

About Weng Fine Art

Weng Fine Art AG (WFA) is a leading art trading company in Europe. The company, based in Monheim am Rhein, was founded in 1994 by Rüdiger K. Weng and has been the only art trading company in Europe listed on the stock exchange since 2012. With currently three business divisions and a team of art, finance and digital experts, the company serves customers all over the world. The company focuses on trading works by internationally renowned 20th and 21st century artists such as Pablo Picasso, Henri Matisse, Edvard Munch, Emil Nolde, Ernst Ludwig Kirchner, Wassily Kandinsky, Andy Warhol, Gerhard Richter, Joseph Beuys, Ai Weiwei, Damien Hirst and Robert Longo.

Weng Fine Art currently concentrates on the business-to-business sector and supplies the major international auction houses as well as renowned dealers and galleries. With its Swiss subsidiary ArtXX AG, WFA operates an e-commerce business for limited serial artworks by the most important contemporary artists under the “Weng Contemporary” brand.

Together with partners from the financial and technology industry, Weng Art Invest is involved in the development of the digital art market based on blockchain technology in order to facilitate access to the art market for collectors and investors and to create transparency for art as an asset class. Further information can be found at: www.wengfineart.com

11 June 2025

Cliq Digital AG: No tender offer by Dylan Media – Request to add resolution on repurchase offer and decrease of the Company's share capital to the AGM agenda

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

Dusseldorf, 11 June 2025 – Today, Cliq Digital AG ("Company") was informed by Dylan Media B.V. ("Dylan Media") that Dylan Media will no longer pursue its previously considered public partial tender offer to the Company's shareholders. Dylan Media further informed the Company that it currently holds around 19.1% of the Company's shares ("Shares") and has entered into purchase agreements relating to further 21.2% of the Shares, thereby increasing Dylan Media's total shareholding to around 40.3% of the Company's share capital.

Dylan Media has further informed the Company about its decision to submit a request to add an agenda item to the Company's upcoming annual general meeting ("AGM 2025") relating to the implementation of a public partial share repurchase offer by the Company to all shareholders of the Company to acquire up to 2,060,000 Shares, corresponding to around 31.65% of the Company's share capital, in exchange for a consideration of EUR 6.06 per Share (representing the volume-weighted average price of the Shares of the six-month period preceding the date hereof plus a 15% premium) ("Potential Partial Repurchase Offer"), combined with a decrease of the Company's share capital by redemption of the Shares to be acquired under the Potential Partial Repurchase Offer. Moreover, Dylan Media informed the Company that it would reserve the right to amend its voting proposal until the AGM 2025 reflecting, in particular, financial information expected to be published before the AGM 2025. Dylan Media also informed the Company that it would irrevocably and unconditionally undertake not to accept the Potential Partial Repurchase Offer for any Shares held by it.

Given the significant changes to the Company’s shareholder structure, the limited demand and liquidity of the Shares, and the capital market no longer being the most viable option for the Company's financing, while facing substantial ongoing listing obligations, expenses and opportunity costs, the Company continues to consider a delisting of the Shares from all stock exchanges to be in the interest and as the right course of action for the Company and intends to decide on a delisting after completion of the Potential Partial Repurchase Offer. The Company will inform the shareholders and the capital market on the result of the Potential Partial Repurchase Offer and the further considerations with regard to a delisting in due course.

Tender Offer for shares of Pharma SGP Holding SE

BIDDER SECTION 10 WPÜG ANNOUNCEMENT
– Convenience Translation –
(Only the German version is legally binding)

THE INFORMATION CONTAINED IN THIS DOCUMENT IS NOT INTENDED FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY COUNTRY WHERE SUCH PUBLICATION, DISTRIBUTION OR TRANSMISSION WOULD BE VIOLATING THE RELEVANT LEGAL PROVISIONS OF SUCH COUNTRY.

Publication of the decision to make a public delisting tender offer (öffentliches Delisting-Erwerbsangebot) pursuant to Section 10 paras. 1 and 3 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz – WpÜG) in conjunction with Section 39 para. 2 sent. 3 no. 1 of the German Stock Exchange Act (Börsengesetz – BörsG)

Bidder:
FUTRUE GmbH
Am Haag 14
82166 Gräfelfing
Germany
registered with the commercial register (Handelsregister) of the local court (Amtsgericht) of Munich under HRB 173092

Target:
PharmaSGP Holding SE
Lochhamer Schlag 1
82166 Gräfelfing
Germany
registered with the commercial register (Handelsregister) of the local court (Amtsgericht) of Munich under HRB 255684
ISIN: DE000A2P4LJ5
WKN: A2P4LJ

Today, FUTRUE GmbH (the “Bidder”) decided to make a public delisting tender offer (öffentliches Delisting-Erwerbsangebot) to the shareholders of PharmaSGP Holding SE (“PharmaSGP”) for the acquisition of all no-par value bearer shares (auf den Inhaber lautende Stückaktien) in PharmaSGP (ISIN DE000A2P4LJ5), each share representing a proportionate amount of EUR 1.00 of the share capital of PharmaSGP (each a “PharmaSGP Share”), which are not directly held by the Bidder, against payment of a cash consideration of EUR 28.00 per PharmaSGP Share (the “Delisting Offer”). The offer price for the Delisting Offer will thus exceed the volume-weighted average share price of the PharmaSGP Shares during the last six months prior to today. The Delisting Offer will not be subject to any closing conditions.

Furthermore, PharmaSGP and the Bidder today entered into a delisting agreement pursuant to which PharmaSGP agreed, amongst others, subject to customary conditions, to support a delisting of PharmaSGP by applying for the revocation of the admission to trading of all PharmaSGP Shares on the regulated market (regulierter Markt) of the Frankfurt Stock Exchange prior to the expiration of the acceptance period of the Delisting Offer. PharmaSGP further undertook in the delisting agreement not to tender the PharmaSGP Shares held by PharmaSGP as treasury shares, corresponding to approximately 4.06% of PharmaSGP’s share capital, into the Delisting Offer.

To offer to PharmaSGP shareholders the aforementioned offer price of EUR 28.00 per PharmaSGP Share without any deduction for dividends received prior to settlement of the Delisting Offer, the Bidder intends to only resolve a statutory minimum dividend of EUR 0.05 per PharmaSGP Share in the upcoming annual general meeting of PharmaSGP.

The Bidder already holds a participation of approximately 82.09% in PharmaSGP’s share capital. Together with voting rights pertaining to further PharmaSGP Shares held by MVH Beteiligungs- und Beratungs-GmbH (“MVH”) which are attributed to the Bidder as a result of a voting agreement with MVH, the Bidder currently controls the voting of PharmaSGP Shares in the aggregate amount of approximately 89.93% of PharmaSGP’s share capital. This corresponds to approximately 93.74% of the share capital and voting rights after deduction of PharmaSGP Shares held by PharmaSGP as treasury shares.

The Bidder hereby announces its firm intention to perform a squeeze-out of the minority shareholders of PharmaSGP in the meaning of Section 327a of the German Stock Corporation Act (Aktiengesetz) (as the case may be, in conjunction with Section 62 para. 5 of the German Transformation Act (Umwandlungsgesetz)) following the settlement of the Delisting Offer and subsequently to enter into a profit and loss transfer agreement (Gewinnabführungsvertrag) in the meaning of Section 291 para. 1 of the German Stock Corporation Act (Aktiengesetz) with PharmaSGP as subordinated enterprise, in each case in cooperation with MVH. It is currently intended that an extraordinary general meeting of PharmaSGP to be held later in 2025 resolves on such squeeze-out.

The offer document for the Delisting Offer (in German, along with a non-binding English translation) containing the detailed terms of the Delisting Offer, as well as further information relating thereto, will be published by the Bidder following clearance by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht - BaFin) at www.futrue-offer.com.

The Delisting Offer will be made subject to the terms set out in the offer document for the Delisting Offer. However, the Bidder reserves the right, to the extent permissible by law, to deviate in the offer document from the above-described parameters.

Important Notice:


This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares in PharmaSGP Holding SE. The Delisting Offer itself as well as its definite terms and further provisions concerning the Delisting Offer, will be published in the offer document following permission by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht – BaFin) to publish the offer document. The Bidder reserves the right to deviate from the key data presented here in the final terms of the Delisting Offer to the extent legally permissible. Investors and holders of shares in PharmaSGP Holding SE are strongly advised to thoroughly read the offer document and all other relevant documents regarding the Delisting Offer when they become available, as they will contain important information.

The Delisting Offer will be published exclusively pursuant to the laws of the Federal Republic of Germany and certain applicable provisions of securities laws of the United States of America. Any agreement that is entered into as a result of accepting the Delisting Offer will be exclusively governed by the laws of the Federal Republic of Germany and is to be interpreted in accordance with such laws. Investors and holders of shares in PharmaSGP Holding SE cannot rely on being protected by the investor protection laws of any jurisdiction other than the Federal Republic of Germany or the United States of America (as applicable). Subject to the exceptions described in the offer document and any exemptions to be granted by the relevant regulatory authorities, no offer will be made, directly or indirectly, in any jurisdiction in which such offer would constitute a violation of the relevant national law.

To the extent permissible under applicable law, the Bidder reserves the right, to purchase additional shares in PharmaSGP Holding SE, directly or indirectly, outside of the Delisting Offer, on or outside the stock exchange. Any such purchases or arrangements will be made in compliance with applicable law. To the extent such acquisitions occur, information about them, including the number of, and the price for, the acquired shares in PharmaSGP Holding SE will be published without undue delay, if and to the extent required under the applicable statutory provisions.

To the extent that this announcement contains forward-looking statements, they are not statements of fact and are identified by the words “intend”, “will” and similar expressions. These statements express the intentions, beliefs or current expectations and assumptions of the Bidder and the persons acting jointly with it. Such forward-looking statements are based on current plans, estimates and projections made by the Bidder and the persons acting jointly with it to the best of their knowledge, but are not guarantees of future accuracy (this applies in particular to circumstances beyond the control of the Bidder or the persons acting jointly with it). Forward-looking statements are subject to risks and uncertainties, most of which are difficult to predict and are usually beyond the Bidder’s control or the control of the persons acting jointly with it. It should be taken into account that actual results or consequences in the future may differ materially from those indicated or contained in the forward-looking statements. It cannot be ruled out that the Bidder and the persons acting jointly with it will change their intentions and estimates stated in documents or notifications or in the offer document yet to be published after publication of the documents, notifications or the offer document.

Gräfelfing, June 10, 2025

FUTRUE GmbH

10 June 2025

PharmaSGP Holding SE: Conclusion of a delisting agreement and announcement of a delisting tender offer by FUTRUE GmbH

Publication of inside information pursuant to Art. 17 para. 1 of Regulation (EU) 596/2014

Gräfelfing, June 10, 2025. Today, PharmaSGP Holding SE (ISIN DE000A2P4LJ5 / WKN A2P4LJ) (“PharmaSGP”) entered into a delisting agreement (the “Delisting Agreement”) with its majority shareholder, FUTRUE GmbH (the “Bidder”). Pursuant to the Delisting Agreement, the Bidder undertook to make an unconditional public delisting tender offer (öffentliches Delisting-Erwerbsangebot) to the shareholders of PharmaSGP to acquire all shares in PharmaSGP not already held by the Bidder for a cash consideration of EUR 28.00 per PharmaSGP Share (the “Delisting Offer”). The offer price for the Delisting Offer will thus exceed the volume-weighted average share price of the PharmaSGP Shares during the last six months prior to today.

Under the Delisting Agreement, PharmaSGP agreed, amongst others, subject to customary conditions, to support a delisting of PharmaSGP by applying for the revocation of the admission to trading of all PharmaSGP Shares on the regulated market (regulierter Markt) of the Frankfurt Stock Exchange prior to the expiration of the acceptance period of the Delisting Offer. PharmaSGP further undertook in the delisting agreement not to tender the PharmaSGP Shares held by PharmaSGP as treasury shares, corresponding to approximately 4.06% of PharmaSGP’s share capital, into the Delisting Offer.

The Bidder already holds a participation of approximately 82.09% in PharmaSGP’s share capital. Together with voting rights pertaining to further PharmaSGP Shares held by MVH Beteiligungs- und Beratungs-GmbH (“MVH”) which are attributed to the Bidder as a result of a voting agreement with MVH, the Bidder currently controls the voting of PharmaSGP Shares in the amount of approximately 89.93% of PharmaSGP’s share capital. This corresponds to approximately 93.74% of the share capital and voting rights after deduction of PharmaSGP Shares held by PharmaSGP as treasury shares.

As a consequence of PharmaSGP’s ownership structure and the limited free float of the PharmaSGP Shares, PharmaSGP believes that equity financing through public capital markets is neither economically viable nor practically achievable. This is also reflected in the decline of the analyst coverage of the PharmaSGP Shares. The listing therefore no longer provides meaningful benefits to PharmaSGP but remains a regulatory burden that entails substantial administrative costs. A delisting of PharmaSGP will significantly reduce the regulatory burden and administration costs due to less stringent legal requirements applying to non-listed companies. Against this background, the management board and the supervisory board of PharmaSGP believe that it is in the best interest of PharmaSGP to pursue the termination of the listing of its shares based on the Delisting Offer as agreed in the Delisting Agreement.

To offer to shareholders of PharmaSGP the aforementioned offer price of EUR 28.00 per PharmaSGP Share without any deduction for dividends received prior to the settlement of the Delisting Offer, the Bidder has informed PharmaSGP that it intends to only resolve a minimum dividend of EUR 0.05 per PharmaSGP Share in the upcoming annual general meeting of PharmaSGP.

In connection with the Delisting Agreement, the Bidder has also communicated to PharmaSGP its firm intention to perform a squeeze-out of the minority shareholders of PharmaSGP in the meaning of Section 327a of the German Stock Corporation Act (Aktiengesetz) (as the case may be, in conjunction with Section 62 para. 5 of the German Transformation Act (Umwandlungsgesetz)) following the settlement of the Delisting Offer and subsequently to enter into a profit and loss transfer agreement (Gewinnabführungsvertrag) in the meaning of Section 291 para. 1 of the German Stock Corporation Act (Aktiengesetz) with PharmaSGP as subordinated enterprise, in each case in coordination with MVH. It is currently intended that an extraordinary general meeting of PharmaSGP to be held later in 2025 resolves on such squeeze-out.

The management board and the supervisory board of PharmaSGP will carefully review the offer document for the Delisting Offer after its publication by the Bidder and issue a reasoned statement in accordance with Section 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz).

04 June 2025

Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with effect from 6 June 2025

Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)


Dreieich, 03 June 2025. The Frankfurt Stock Exchange today informed Biotest AG that it has approved the company's application to revoke the admission of Biotest shares (ordinary shares of Biotest AG: ISIN°DE0005227201, Biotest AG preference shares: ISIN DE0005227235) from trading on the regulated market of the Frankfurt Stock Exchange and in the segment of the regulated market with additional post-admission requirements (Prime Standard).

In accordance with the end of the acceptance period specified in the offer document for the public delisting offer by Grifols Biotest Holdings GmbH, the delisting will take effect at the end of 6 June 2025.

After this date, the shares of Biotest AG will no longer be traded on the Frankfurt Stock Exchange and the additional listing requirements will no longer apply.

Biotest Aktiengesellschaft
Board of Management